Description

Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), modified with the addition of a trans-3-hexenoic acid group at the N-terminal. This modification increases its stability and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). In the field of endocrinology, Tesamorelin is the primary entity studied for its highly selective ability to reduce Visceral Adipose Tissue (VAT) without significantly impacting subcutaneous fat or glucose homeostasis.

Performance Peptides Canada offers Tesamorelin 10mg vials at 99%+ HPLC-verified purity. Our domestic fulfillment ensures that researchers receive high-stability ligands optimized for studying lipodystrophy, hepatic steatosis, and growth hormone pulsatility in Canada.

Technical Specifications & Chemical Profile

Our Tesamorelin is synthesized to meet rigorous analytical standards:

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S₁
• Molecular Weight: 5135.9 g/mol
• Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
• Purity: ≥99.0% (Verified via HPLC/MS)
• CAS Number: 218949-48-5
• Form: Lyophilized white powder

Primary Research Mechanisms & Metabolic Impact

Tesamorelin is distinguished from other GHRH analogs like CJC-1295 by its specific regulatory approvals and targeted fat metabolism.

1. Selective Visceral Adipose Tissue (VAT) Reduction

Tesamorelin acts on the pituitary somatotrophs to stimulate the synthesis and pulsatile release of endogenous growth hormone. Unlike standard GH therapy, Tesamorelin is studied for its ability to specifically reduce VAT—the deep “organ fat” associated with cardiovascular risk and metabolic syndrome—while preserving insulin sensitivity.

2. Reduction of Hepatic Fat (NAFLD Research)

Recent research utilizes Tesamorelin to investigate Non-Alcoholic Fatty Liver Disease (NAFLD). By increasing GH levels, it appears to reduce liver fat accumulation and improve markers of hepatic inflammation. This makes it a vital tool for studying the link between the GH/IGF-1 axis and liver health.

3. Preservation of Natural GH Pulsatility

Because Tesamorelin is a GHRH analog rather than exogenous GH, it maintains the natural feedback loop involving somatostatin. Researchers use it to study growth hormone signaling that more closely mimics physiological rhythms, avoiding the “square wave” GH elevation that can lead to receptor downregulation.

Reconstitution & Stability Benchmarks

As a 44-amino acid peptide, Tesamorelin requires careful handling to maintain its secondary structure:

• Reconstitution: Recommended diluents are Bacteriostatic Water or 0.9% Sterile Saline.
• Solubility: Highly soluble in aqueous solutions. Gently introduce 2mL of diluent. Swirl slowly; do not shake, as this may denature the long peptide chain.
• Storage: Store lyophilized powder at -20°C. Once reconstituted, keep refrigerated at 2°C to 8°C.

Stability Data

Tesamorelin Research FAQ

Q: Is Tesamorelin the same as CJC-1295?

A: No. While both are GHRH analogs, Tesamorelin is a 44-amino acid sequence with a specific N-terminal modification that makes it the primary entity for visceral fat research. CJC-1295 is a shorter 29-amino acid fragment designed for different research endpoints.

Q: Does Tesamorelin raise IGF-1 levels?

A: Yes. By stimulating the release of GH, Tesamorelin subsequently increases the production of IGF-1 in the liver. Researchers monitor IGF-1 levels as a proxy for the biological activity and efficacy of the peptide.

Q: Why is the domestic shipping from Canada important?

A: Tesamorelin is a high-value, sensitive peptide. Performance Peptides Canada ensures all orders are shipped domestically, bypassing the risk of customs seizures and prolonged exposure to high temperatures in international sorting facilities.